share_log
Moomoo 24/7 ·  Mar 14 12:52
Immuneering Shares Are Trading Lower After the Company Announced Topline Result From the Ongoing Phase 1 Portion of Its Phase 1/2a Clinical Trial of IMM-1-104 in Advanced RAS-mutant Solid Tumors
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment